How affordable are targeted therapies in non-small cell lung cancer?

Current Treatment Options in Oncology

Volumn 12, Issue 1, 2011, Pages 1-11

  Coate, Linda E ^a   Leighl, Natasha B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HEALTH CARE COST; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS;

EID: 78751647585     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-010-0137-x     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. (Pubitemid 351521864)
2. Aggarwal S: Targeted cancer therapies. Nat Rev Drug Discov 2010, 9:427-428.
3. Sandler A, Gray R, Perry MC, et al.: Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006, 355:2542-2550. (Pubitemid 44917502)
4. Herbst RS, Sandler ATreatment Outcomes by Tumor Histology in Eastern Cooperative Group (ECOG) Study E4599 of Bevacizumab (BV) with Paclitaxel/Carboplatin (PC) for Advanced Non-small Cell Lung Cancer (NSCLC).: Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? J Thorac Oncol 2008 3: S283.
5. Reck M, von Pawel J, Zatloukal P, et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
6. Pirker R, Pereira JR, Szczesna A, et al.: Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
7. Lynch TJ, Patel T, Dreisbach L, et al.: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
8. Scagliotti GV, Parikh P, von Pawel J, et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
9. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
10. Maemondo M, Inoue A, Kobayashi K, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
11. Soon YY, Stockler MR, Askie LM, et al.: Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009, 27:3277-3283.
12. Ciuleanu T, Brodowicz T, Zielinski C, et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
13. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009, 27:8001.
14. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103. (Pubitemid 30324363)
15. Hanna N, Shepherd FA, Fossella FV, et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597. (Pubitemid 41079796)
16. Douillard JY, Shepherd FA, Hirsh V, et al.: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132. (Pubitemid 41058344)
18. Bang Y, Kwak EL, Shaw AT, et al.: Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:3.
19. Shaw AT, Costa D, Mino-Kenudson M, et al.: Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol 2009, 27:11021.
20. Molinier L, Combescure C, Chouaid C, et al.: Cost of lung cancer: a methodological review. Pharmacoeconomics 2006, 24:651-659. (Pubitemid 43998818)
21. Holmes J, Dunlop D, Hemmett L, et al.: A costeffectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004, 22:581-589. (Pubitemid 38943103)
22. Neymark N, Lianes P, Smit EF, et al.: Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 2005, 23:1155-1166. (Pubitemid 41633404)
23. Szczepura A: Healthcare outcomes: gemcitabine costeffectiveness in the treatment of non-small cell lung cancer. Lung Cancer 2002, 38(2):S21-S28. (Pubitemid 35300445)
24. Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
25. Arrieta O A P, López RJ, Polanco AC: Cost-effectiveness analysis of EGFR mutation testing patients with advanced non small-cell lung cancer treated with gefitinib or carboplatin-paclitaxel. ISPOR 15th Annual International Meeting Atlanta, GA, USA May, 2010.
26. Kim ES, Hirsh V, Mok T, et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
27. Horgan AM, Shepherd FA, Bradbury PA, et al.: Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer. J Clin Oncol 2008, 26:8110.
28. Chouaid C, Monnet I, Robinet G, et al.: Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr Med Res Opin 2007, 23:1509-1515. (Pubitemid 47122159)
29. Leighl NB, Tsao WS, Zawisza DL, et al.: A willingnessto-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006, 51:115-121. (Pubitemid 43088631)
30. van Zandwijk N: Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. Lung Cancer 2006, 51:137-138.
31. Ramsey SD, Martins RG, Blough DK, et al.: Secondline and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008, 14:297-306.
32. Ramsey SD, Clarke L, Kamath TV, et al.: Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U. S. health insurance plan. J Manag Care Pharm 2006, 12:472-478.
33. Lyseng-Williamson KA: Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010, 28:75-92.
34. Bradbury PA, Tu D, Seymour L, et al.: Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010, 102:298-306.
35. Grusenmeyer PA, Gralla RJ: Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 2006, 24:6057.
36. Drucker A, Virik K, Skedgel C, et al.: The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: can we afford it? J Clin Oncol 2006, 24:6044.
37. Fleeman N, Bagust A, McLeod C, et al.: Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010, 14 (Suppl 1):47-53.
38. Vrouchou P, Kandaswamy P, George E, et al.: Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal. Lancet Oncol 2009, 10:1031-1032.
39. NICE: Pemetrexed for the first-line treatment of nonsmall cell lung cancer. Final Appraisal Determination. August, 2009. http://www.nice.org.uk/ nicemedia/pdfFADPemetrexedLungCancer.pdf, 2009.
40. Asukai Y, Valladares A, Camps C, et al.: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 2010, 10:26.
41. Nadler E, Eckert B, Neumann PJ: Do oncologists believe new cancer drugs offer good value? Oncologist 2006, 11:90-95. (Pubitemid 43261756)